A new study reveals that antimicrobial resistance is rising worldwide - eroding the effectiveness of last-line antibiotics ...

OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment-related laboratory findings, no ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA ...

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Repare Therapeutics Inc. ("Repare" or the "Company") , a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's ...

The study has a two-part, placebo-controlled, double-blind, randomised, dose-escalation (single ascending dose) design.

Ascentage Pharma Group International (HK:6855) announced an update on their ongoing clinical study.

SN Bioscience Inc. (CEO Young Hwan PARK) announced that the FDA had granted Orphan Drug Designation (ODD) on December 10 for gastric cancer (including gastroesophageal junction cancer) ...

Learn how therapies to clinic are evolving with peptide medicines, offering new solutions for oncology and metabolic ...